Latest News

Study finds systemic AD treatment relieves depressive symptoms along with skin symptoms


 

FROM ISAD 2022


Dr. Joseph pointed out that taking the deep dive also involves being prepared for what comes up. “Once you’ve established there’s a mental health issue, what do you do then?” she said. “If you are a dermatologist, is that in your wheelhouse to address? There’s the education and connection piece for the physician, creating networks where – if you identify a patient who has an issue – who is a person I can send them to? We have these types of connections with infectious disease or with ophthalmologists if there are ocular symptoms, but mental health is one area where there may not be as much support for dermatologists.”

She noted that though all doctors learn how to screen for depression, “there’s the formulaic, yes/no answers, and then there’s the nuanced history-taking, creating a safe space, where the patient is going to answer you fulsomely ... and feel heard. Many of us know how to do that. The question is time.”

Dr. Ivert had no disclosures connected to this study. Dr. Joseph had no disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Why it’s important for dermatologists to learn about JAK inhibitors
MDedge Internal Medicine
Abrocitinib evaluated in patients with and without prior dupilumab treatment
MDedge Internal Medicine
VTE risk not elevated in AD patients on JAK inhibitors: Study
MDedge Internal Medicine
Dupilumab offers ‘clinically meaningful’ improvements in prurigo nodularis
MDedge Internal Medicine
Roflumilast foam effectively eases seborrheic dermatitis
MDedge Internal Medicine
Many factors linked with higher, lower risk for hand eczema
MDedge Internal Medicine
FDA approves dupilumab for treatment of prurigo nodularis
MDedge Internal Medicine
52-week data show lebrikizumab atopic dermatitis effects maintained
MDedge Internal Medicine
Dermatologists fear effects of Dobbs decision for patients on isotretinoin, methotrexate
MDedge Internal Medicine
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Internal Medicine